Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles ImmuCell Corporation’s (Nasdaq: ICCC) SEC filings, giving investors structured access to the company’s regulatory disclosures as an animal health business focused on dairy and beef cattle. ImmuCell’s filings include current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, along with other exhibits and agreements.
Through these documents, readers can review ImmuCell’s reported product sales for its First Defense® line, commentary on trends in domestic and international sales, and management’s discussion of gross margins, net income or loss, and backlog dynamics. Filings also describe the development status of Re-Tain®, including the New Animal Drug Application process, investigational product use, and the company’s decision to pause further direct investment after receiving an FDA Incomplete Letter related to a contract manufacturer.
ImmuCell’s SEC reports provide detail on financing arrangements, such as loan agreements and lines of credit with Maine Community Bank, refinancing transactions, and related security interests in company assets. They also disclose corporate governance and leadership changes, including CEO succession, board expansion, and executive employment agreements, as well as other material definitive agreements.
On Stock Titan, these filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain lengthy 10-K and 10-Q reports, highlight key risk factors and business updates, and clarify the implications of Form 8-K events. Users can also quickly identify information about executive and board changes, financing obligations and other material developments affecting ImmuCell’s cattle health-focused operations.
ImmuCell Corporation reported that two directors, Steven A. Rosgen and Bryan K. Gathagan, have each notified the company that they prefer not to run for re-election at the 2026 Annual Meeting of Shareholders. Both directors are described as supportive of the company’s new strategic direction and management team, but cited time constraints from full-time leadership roles at their own companies. The Board’s Nominating Committee has been reviewing possible changes to Board composition and will now incorporate these planned retirements into its ongoing work.
ImmuCell Corporation updated compensation arrangements for key executives. Effective January 27, 2026, new employment agreements set annual base salaries of $315,000 for CFO Timothy C. Fiori and $300,000 for Senior VP of Sales and Marketing Bobbi Jo Brockmann. Beginning with the fiscal year ending December 31, 2026, each can earn a formula-based annual cash bonus targeting 50% of base salary, rising to 60% if preset financial and strategic targets are exceeded by at least 20%. The Compensation and Stock Option Committee also granted Fiori an option for 120,000 shares and Brockmann an option for 100,000 shares under the 2025 Stock Option and Incentive Plan, vesting in three equal annual installments from January 2027 at an exercise price of $6.26 per share, with potential accelerated vesting upon a change of control or certain terminations. CEO Olivier te Boekhorst received a performance-based option for 110,000 shares at $6.26 per share, vesting only if net operating income for four consecutive quarters reaches at least 300% of audited 2025 net operating income.
ImmuCell Corporation filed a Form 4 for Chief Financial Officer and director Timothy C. Fiori reporting a new stock option grant. On January 27, 2026, he received 120,000 stock options with an exercise price of $6.265 per share, held directly.
The option is intended to qualify as an incentive stock option to the maximum extent allowed under the Internal Revenue Code, with the remainder as a nonqualified option. It vests in three equal tranches of 40,000 options on each of the first, second, and third anniversaries of the grant date.
ImmuCell Corporation filed a Form 4 showing an option grant to executive and director Bobbi Jo Brockmann. On January 27, 2026, she received stock options to purchase 100,000 shares of common stock at an exercise price of $6.265 per share, expiring on January 27, 2036.
The options were granted in connection with her role as Vice President of Sales and Marketing. They vest over three years: 33,333 shares become exercisable on each of January 27, 2027 and January 27, 2028, and 33,334 shares become exercisable on January 27, 2029. Following this grant, she beneficially owns 100,000 derivative securities directly.
Immucell Corporation reported a new equity award to its President and CEO, Paul Francis Olivier te Boekhorst. On January 27, 2026, he was granted 110,000 stock options with an exercise price of $6.265 per share.
The option is intended to qualify as an incentive stock option to the maximum extent allowed, with any remainder treated as a nonqualified option. All of the options will vest only if Immucell’s net operating income for four consecutive calendar quarters reaches at least 300% of its audited net operating income for the 2025 fiscal year.
ImmuCell Corporation reported that it has released preliminary, unaudited sales results for the three‑month and twelve‑month periods ended December 31, 2025, via a January 8, 2026 press release. The company also disclosed that it will record approximately $3.6 million in non‑cash impairment write‑downs for the quarter ended December 31, 2025, and stated it does not expect these charges to lead to material future cash expenditures, although actual amounts may differ from current estimates.
The company highlighted a strategic shift toward its First Defense® product line and away from Re‑Tain®, and scheduled a conference call on January 9, 2026 to discuss top‑line results and this shift. A second conference call is planned for February 26, 2026 to review full, unaudited financial results for the quarter and year ended December 31, 2025, which the company expects to release after market close on February 25, 2026.
ImmuCell Corporation (ICCC) reported Q3 2025 results. Product sales were $5,506,122 versus $6,011,573 a year ago, and the quarter showed a net loss of $139,748 compared with a loss of $701,690 last year. Gross margin improved to $2,363,098 from $1,583,554 as costs of goods sold declined.
For the nine months ended September 30, 2025, product sales reached $20,018,175 versus $18,742,040, and net income was $1,809,115 versus a loss of $2,671,184 last year. Cash and cash equivalents were $3,886,198. Inventory stood at $9,802,005. Total liabilities were $15,929,282 and stockholders’ equity was $29,800,841.
Capital and financing: During Q3 2025, the company refinanced prior loans into a new $2,327,119 MCB term loan at a fixed 6.5% rate, replacing 7% and 8% debt, removing July 2026 balloon payments and setting monthly payments of $45,637 through the third quarter of 2030.
Concentration: Two customers represented 68% of Q3 product sales. Shares outstanding were 9,045,851 as of October 31, 2025.
ImmuCell Corporation furnished an 8-K announcing it issued a press release with unaudited financial results for the quarter ended September 30, 2025. The disclosure is under Item 2.02 and is expressly stated as furnished, not filed, which limits liability under Section 18.
The filing includes Exhibit 99.1 (press release dated November 13, 2025) and Exhibit 104 (cover page Inline XBRL).
ImmuCell Corp (ICCC)74,277 stock options at an exercise price of $6.10 on November 7, 2025.
The options vest in three equal tranches of 24,759 on the first, second, and third anniversaries of the grant and expire on November 7, 2035. The award will be treated as an incentive stock option to the maximum extent permitted, with the balance as a nonqualified option. Following the grant, the officer beneficially owned 150,260 derivative securities.
ImmuCell (ICCC)$5.90 per share, covering 25,327, 25,327, and 25,329 shares. These options become exercisable on 09/16/2026, 09/16/2027, and 09/16/2028, respectively, and each expires on 09/16/2035. The grant was made in connection with an offer letter outlining the terms of his employment and vests in three increments as shown.
FAQ
What is the current stock price of Immucell (ICCC)?
What is the market cap of Immucell (ICCC)?
